Critical Review: Bausch + Lomb (NYSE:BLCO) and Pulse Biosciences (NASDAQ:PLSE)

Pulse Biosciences (NASDAQ:PLSE – Get Free Report) and Bausch + Lomb (NYSE:BLCO – Get Free Report) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.

Profitability

This table compares Pulse Biosciences and Bausch + Lomb’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pulse Biosciences -5,603.88% -77.88% -67.89%
Bausch + Lomb -2.05% 5.01% 2.34%

Earnings and Valuation

This table compares Pulse Biosciences and Bausch + Lomb”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pulse Biosciences $350,000.00 9,422.81 -$72.78 million ($1.21) -37.06
Bausch + Lomb $5.10 billion 1.46 -$360.00 million ($0.31) -67.20

Pulse Biosciences has higher earnings, but lower revenue than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Pulse Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for Pulse Biosciences and Bausch + Lomb, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pulse Biosciences 1 0 5 1 2.86
Bausch + Lomb 1 8 5 1 2.40

Pulse Biosciences presently has a consensus target price of $66.60, suggesting a potential upside of 48.53%. Bausch + Lomb has a consensus target price of $21.08, suggesting a potential upside of 1.20%. Given Pulse Biosciences’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Pulse Biosciences is more favorable than Bausch + Lomb.

Institutional and Insider Ownership

77.0% of Pulse Biosciences shares are held by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are held by institutional investors. 74.0% of Pulse Biosciences shares are held by insiders. Comparatively, 1.4% of Bausch + Lomb shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Pulse Biosciences has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500.

Summary

Pulse Biosciences beats Bausch + Lomb on 7 of the 12 factors compared between the two stocks.

About Pulse Biosciences

(Get Free Report)

Pulse Biosciences, Inc. develops medical devices using its proprietary nanosecond pulsed field ablation (nsPFA) technology. The technology delivers very short electrical pulses intended to disrupt targeted cells without relying on heat, with the goal of limiting effects on surrounding tissue. The company is developing nsPFA applications for cardiac electrophysiology and surgical oncology, including devices for tissue ablation. Its earlier CellFX System brought the technology to dermatology for treating certain benign skin lesions, marking an initial commercial application of the platform.

About Bausch + Lomb

(Get Free Report)

Bausch + Lomb Corporation is an eye-health company that develops, manufactures and markets products for consumers, eye-care professionals and surgical teams. Its business spans vision care, pharmaceuticals and surgical devices. Its products include contact lenses and lens-care solutions, as well as eye-health medicines and nutritional supplements. The company also supplies equipment, technologies and related products used in eye surgery and other ophthalmic procedures. Founded in Rochester, New York, in 1853 by John Jacob Bausch and Henry Lomb, the company serves customers in more than 100 countries.

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.